个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Song, Yuqin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] * ; Zhu, Jun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Lin, Ningjing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Mingzhi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Bai, Hai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Liu, Hui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Cui, Jie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Ke, Xiaoyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Huilai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Liu, Lihong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Yan, Dongmei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Jiang, Yongsheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zang, Aimin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Qi, Junyuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Wang, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Liu, Zhuogang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Xu, Bing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Zhang, Zhihui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ; Meng, Haijin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19] ;
机构： [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China [2]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [3]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [4]940 Hosp Joint Logist Support Force PLA, Lanzhou, Peoples R China [5]Beijing Hosp, Beijing, Peoples R China [6]Canc Hosp Gansu Prov, Lanzhou, Peoples R China [7]Peking Univ, Hosp 3, Beijing, Peoples R China [8]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [9]Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Hebei, Peoples R China [10]Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China [11]Huangzhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [12]Hebei Med Univ, Affiliate Hosp, Baoding, Peoples R China [13]Chinese Acad Med Sci, Hematol Hosp, Tianjin, Peoples R China [14]Peoples Hosp Jiangsu Prov, Nanjing, Peoples R China [15]China Med Univ, Shengjing Hosp, Shenyang, Peoples R China [16]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China [17]Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China [18]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [19]Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China
出处：
ISSN：
基金：
Guangzhou Gloria Biosciences Co,. Ltd.
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China [2]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [3]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [4]940 Hosp Joint Logist Support Force PLA, Lanzhou, Peoples R China [5]Beijing Hosp, Beijing, Peoples R China [6]Canc Hosp Gansu Prov, Lanzhou, Peoples R China [7]Peking Univ, Hosp 3, Beijing, Peoples R China [8]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [9]Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Hebei, Peoples R China [10]Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China [11]Huangzhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [12]Hebei Med Univ, Affiliate Hosp, Baoding, Peoples R China [13]Chinese Acad Med Sci, Hematol Hosp, Tianjin, Peoples R China [14]Peoples Hosp Jiangsu Prov, Nanjing, Peoples R China [15]China Med Univ, Shengjing Hosp, Shenyang, Peoples R China [16]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China [17]Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China [18]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [19]Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Song Yuqin,Zhu Jun,Lin Ningjing,et al.Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):
APA：
Song, Yuqin,Zhu, Jun,Lin, Ningjing,Zhang, Mingzhi,Bai, Hai...&Meng, Haijin.(2020).Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA：
Song, Yuqin,et al."Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号